Trovagene Investor Relations http://trovageneoncology.investorroom.com/ Trovagene Investor Relations New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML http://trovageneoncology.investorroom.com/2018-12-03-New-Data-from-Phase-1b-2-Study-of-Onvansertib-in-Combination-with-LDAC-or-Decitabine-Demonstrates-Response-to-Treatment-in-Relapsed-Refractory-AML - Preliminary Anti-Leukemic Activity Demonstrates >80% Response to Treatment with Onvansertib in Combination with Low-Dose Cytarabine (LDAC) or Decitabine in Dose Escalation Phase 1b of Trial Mon, 03 Dec 2018 08:00:00 -0800 http://trovageneoncology.investorroom.com/2018-12-03-New-Data-from-Phase-1b-2-Study-of-Onvansertib-in-Combination-with-LDAC-or-Decitabine-Demonstrates-Response-to-Treatment-in-Relapsed-Refractory-AML Trovagene, Inc. Receives Positive Nasdaq Listing Decision http://trovageneoncology.investorroom.com/2018-11-15-Trovagene-Inc-Receives-Positive-Nasdaq-Listing-Decision Thu, 15 Nov 2018 05:30:00 -0800 http://trovageneoncology.investorroom.com/2018-11-15-Trovagene-Inc-Receives-Positive-Nasdaq-Listing-Decision Trovagene Announces Launch of New Company Website http://trovageneoncology.investorroom.com/2018-11-13-Trovagene-Announces-Launch-of-New-Company-Website New website offers visitors greater insight into the Company's focus in oncology drug development, predictive clinical biomarkers and advances in Onvansertib clinical program Tue, 13 Nov 2018 05:30:00 -0800 http://trovageneoncology.investorroom.com/2018-11-13-Trovagene-Announces-Launch-of-New-Company-Website Trovagene Announces Third Quarter 2018 Highlights and Financial Results http://trovageneoncology.investorroom.com/2018-11-07-Trovagene-Announces-Third-Quarter-2018-Highlights-and-Financial-Results Wed, 07 Nov 2018 13:20:00 -0800 http://trovageneoncology.investorroom.com/2018-11-07-Trovagene-Announces-Third-Quarter-2018-Highlights-and-Financial-Results Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting http://trovageneoncology.investorroom.com/2018-11-01-Trovagene-to-Present-Data-from-Lead-Clinical-Program-of-Onvansertib-in-Acute-Myeloid-Leukemia-at-the-60th-American-Society-of-Hematology-Annual-Meeting Targeted treatment with highly-selective, oral Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with standard-of-care chemotherapy may represent a new treatment option in AML Thu, 01 Nov 2018 07:36:00 -0700 http://trovageneoncology.investorroom.com/2018-11-01-Trovagene-to-Present-Data-from-Lead-Clinical-Program-of-Onvansertib-in-Acute-Myeloid-Leukemia-at-the-60th-American-Society-of-Hematology-Annual-Meeting